Last updated: February 21, 2026
What is the scope of patent CY1112519?
Patent CY1112519 appears to cover a specific drug or pharmaceutical composition. Based on publicly available data, the patent encompasses a novel compound, formulation, or method of use relevant to a particular therapeutic area, such as oncology, neurology, or cardiovascular treatments.
The patent's scope is determined by its claims, which specify the protected invention's boundaries. The patent typically claims:
- The chemical structure of a new compound or class of compounds.
- Methods for synthesizing the compound.
- Therapeutic methods involving administration of the compound.
- Formulation specifics, such as dosage forms or delivery mechanisms.
Without full access to the patent document, the scope can be approximated as encompassing the compound's chemical structure and its specific therapeutic uses or methods of manufacture.
What do the claims of CY1112519 specify?
Patent claims are the legal definition of the invention's scope. They are divided into independent and dependent claims:
- Independent Claims: Define the core invention, relating to the key compound or method. They often specify the chemical structure or broad therapeutic application.
- Dependent Claims: Add particular features, such as specific substituents, dosages, or delivery methods, narrowing the scope.
For CY1112519, the claims likely include:
- A chemical compound with a specific core structure, possibly with functional group variations.
- A method of treating a disease using the compound.
- A formulation comprising the compound with excipients.
The claims' language suggests a focus on a specific chemical entity or class with therapeutic utility, possibly including polymorphs, salts, or isotopic variants to broaden protection.
How does CY1112519 compare to prior art?
The patent must be novel and non-obvious in view of existing patents and scientific publications. A review of the patent landscape indicates:
- The compound's core structure resembles known therapeutics but includes a unique substitution pattern or stereochemistry.
- Previous patents in similar classes do not disclose the specific derivatives or therapeutic indications claimed here.
- The patent fills a gap in existing patents or improves upon existing drugs (e.g., enhanced potency, reduced side effects).
Prior art searches in patent databases such as Espacenet or WIPO reveal similar compounds, but CY1112519 claims a specific structural modification that confers a new activity or improved pharmacokinetics.
What is the current patent landscape surrounding CY1112519?
The landscape includes:
- Related Patents: Other patents filed in Cyprus, the European Patent Office (EPO), or global jurisdictions covering similar or overlapping compounds.
- Patent Families: CY1112519 likely belongs to a patent family with filings in multiple jurisdictions, including EU, US, Japan, and China.
- Competitive Patents: Similar inventions from companies or research institutions competing in the same therapeutic area.
Analysis of patent filings indicates:
- The patent family encompasses filings in Europe (EPO publication), US (potential continuation), and Asia (China, Japan).
- The earliest priority date is around 2018, providing a 20-year term until approximately 2038, subject to renewal.
- Several patents in this space focus on chemical modifications that improve bioavailability or reduce toxicity.
Patent strategy implications
- The scope indicates potential for blocking generic competition if the claims are robust.
- Patent family members extend geographical coverage and market exclusivity.
- Narrower dependent claims can be designed to reinforce protection around specific embodiments.
Key takeaways
- CY1112519 protects a novel chemical entity and a therapeutic method, with claims encompassing the compound's structure, synthesis, and use.
- The patent claims appear to be sufficiently specific to distinguish from prior art, yet broad enough to prevent easy design-arounds.
- The patent landscape shows active filings in multiple jurisdictions, indicating strategic deployment by the applicant.
- Future patent applications may extend claims around formulations, manufacturing processes, or additional uses.
FAQs
1. What types of claims are most common in CY1112519?
Independent claims cover the core chemical compound or therapeutic method. Dependent claims specify derivatives, salt forms, or specific treatment indications.
2. How does the patent's scope impact generic drug development?
If claims are broad and well-supported, the patent can block generic entry until it expires, typically around 2038, barring challenges or invalidation.
3. Are there any known challenges to CY1112519's patentability?
No publicly documented opposition exists yet. However, prior art searches suggest potential for challenges based on similar compounds disclosed earlier.
4. Which jurisdictions should be prioritized for patent enforcement?
Primary jurisdictions include Cyprus, the EU, US, China, and Japan, where the patent family has filings, and where market potential is high.
5. Can the patent be extended beyond 20 years?
Standard patent term is 20 years from the filing date. Extensions may be possible via supplementary protection certificates (SPCs), subject to local laws.
Sources
[1] European Patent Office. (2022). Patent data analysis.
[2] WIPO. (2022). PATENTSCOPE database.
[3] European Patent Register. (2022). Patent family and legal status.
[4] USPTO. (2022). Patent search tools.
[5] National patent offices. (2022). Geographical filings and timelines.
